Carfilzomib‐Based Quadruplets Challenge VRd as Frontline Multiple Myeloma Backbone
Written by
American Journal Managed Care
Published
0
comments
0
min
Emerging data suggest that isatuximab‐KRd and daratumumab‐KRd produce superior depth of response compared with KRd alone, with sustained MRD negativity and encouraging progression‐free survival in NDMM.